Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection

INTRODUCTION: Nivolumab demonstrated significant recurrence-free survival (RFS) gains versus ipilimumab in the CheckMate-238 trial, whereas the CA184-029 trial showed superior RFS gains for ipilimumab versus placebo. No head-to-head trial data were available to compare the efficacy of nivolumab to t...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacoecon Open
Asıl Yazarlar: Batteson, Rachael, Hart, Rose, Hemstock, Matthew, Gooden, Kyna, Kotapati, Srividya, Roze, Stephane, Lee, Dawn, Amadi, Adenike
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2019
Konular:
Original Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248152/
https://ncbi.nlm.nih.gov/pubmed/31587138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-00181-y
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller